Skip to main content
SpringerLink
Log in

Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Defibrotide is a polynucleotide extracted from mammalian lung, which shows antithrombotic and anti-ischaemic activity in animals, probably related to stimulation of fibrinolysis and/or enhancement of prostacyclin production. The effect of a single infusion of defibrotide on fibrinolysis and the levels of certain prostanoids in man has been investigated in a cross-over double-blind placebo-controlled study.

Evaluation of changes in fibrinolysis was difficult because of the spontaneous activation observed after placebo. However, the fast-acting plasminogen activator inhibitor was decreased only at end of the defibrotide infusion, suggesting a moderate profibrinolytic effect superimposed on the spontaneous activation.

There was a marked and prolonged elevation of the plasma level of 6-keto-PGF1α, the stable metabolite of prostacylcin. In collagen stimulated whole blood, both 6-keto-PGF1α and prostaglandin E2 production were also greatly increased, with no consistent indication of inhibition of thromboxane B2. It is suggested that defibrotide stimulates prostacyclin and prostaglandin E2 production by leucocytes or via platelet/leukocyte interactions. The effects observed here should be useful in guiding subsequent clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Niada R, Mantovani M, Prino G, Pescador R, Nardi GF (1979) Antithrombotic activity of polydeoxyribonucleotide of mammalian origin (laboratory code: Fraction P) in experimental animals. Thromb Haemost 42: 474

    Google Scholar 

  2. Pescador R, Mantovani M, Prino G, Madonna M (1983) Pharmacokinetics of Defibrotide and of its profibrinolytic activity in the rabbit. Thromb Res 30: 1–11

    Google Scholar 

  3. Niada R, Mantovani M, Prino G, Pescador R, Berti F, Omini C, Folco GC (1981) Antithrombotic activity of a polydeoxyribonucleotide substance extracted from mammalian organs A possible link with prostacyclin. Thromb Res 23: 233–246

    Google Scholar 

  4. Mussoni L, Evolvi C, Donati MB (1979) Activation of plasma and vascular fibrinolytic activity by a polydeoxyribonucleotidic substance, Fraction P, in rats and rabbits. Thromb Haemost 42: 388

    Google Scholar 

  5. Lobel P, Schrör K (1985) Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by Defibrotide in the platelet perfused heart. Naunyn-Schmiedebergs Arch Pharmacol 331: 125–130

    Google Scholar 

  6. Thiemermann C, Lobel L, Schrör K (1985) Usefulness of Defibrotide in protecting ischemic myocardium from early reperfusion damage. Am J Cardiol 56: 978–982

    Google Scholar 

  7. Berti F, Rossoni G, Niada R, Folco GC, Omini C, Tondo C (1986) Defibrotide, an antithrombotic substance which preserve postsynaptic alpha- and beta-adrenergic function in post acute infarcted rabbit hearts. J Cardiovasc Pharmacol 8: 235–240

    Google Scholar 

  8. Berti F, Rossoni G, Omini C, Folco GC, Daffonchio L, Vigano' T, Tondo C (1987) Defibrotide, an antithrombotic substance which prevents myocardial contracture in ischemic rabbit heart. Eur J Pharmacol 135: 375–382

    Google Scholar 

  9. Noseda G, Fragiacomo C, Ferrari D (1986) Pharmacokinetics of Defibrotide in healthy volunteers. Haemostasis 16 [Suppl 1]: 26–30

    Google Scholar 

  10. Burton K (1956) The conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62: 315–323

    Google Scholar 

  11. Kaulla von KN, Schultz RL (1958) Methods for the evaluation of human fibrinolysis. Am J Clin Pathol 29: 104–108

    Google Scholar 

  12. Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G (1982) A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurement in plasma. Thromb Haemost 48: 266–269

    Google Scholar 

  13. Chmielewska J, Ramby M, Wiman B (1983) Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 31: 427–436

    Google Scholar 

  14. Granstöm E, Kindahl H (1978) Radioimmunoassay of prostaglandins and thromboxane. In: Frölich JC (ed) Advances in prostaglandin and thromboxane research. Raven Press, New York, pp 119–210

    Google Scholar 

  15. Defreyn G, Deckmyn H, Vermylen J (1982) A thromboxane synthetase inhibitor reorients endoperoxides metabolism in whole blood toward prostacyclin and prostaglandin E2. Thromb Res 26: 389–400

    Google Scholar 

  16. Li CC (1964) Introduction to experimental statistics. Mc Graw Hill, New York, pp 207–226

    Google Scholar 

  17. Grimaudo V, Kruithof EKO, Hauert J, Bachmann F (1987) Diurnal variation of components of the fibrinolytic system. Thromb Haemost 58: 430

    Google Scholar 

  18. Kluft C, Verheijen JH, Rijken DC, Chang GTG, Jie AFH, Onkelinx C (1985) Diurnal fluctations in the activity of the fast-acting t-PA inhibitor. In: Davidson JF, Donati MB, Coccheri S (eds) Progress in fibrinolysis, vol. III. Churchill Livingstone, Edinburgh, pp 117–119

    Google Scholar 

  19. Coccheri S, De Rosa V, Dettori AG, Ponari O, Bizzi B, Ciavarella N, Isidori A (1982) Effect on fibrinolysis of a new antithrombotic agent: Fraction P (Defibrotide). A multicenter trial. Int J Clin Pharmacol Res 2: 227–245

    Google Scholar 

  20. Vittoria A, Messa GL, Berri F, De Giovanni F, Buzzetti G, Di Perri T (1985) Effect of Defibrotide administered i.v., i.m. and per os on some fibrinolytic parameters in man. Controlled study versus placebo. In: Davidson JF, Donati MB, Coccheri S (eds) Progress in fibrinolysis, vol. VII. Churchill Livingstone, Edinburgh, pp 329–335

    Google Scholar 

  21. Ulutin ON, Ilhan-Berkel N, Balkuv-Ulutin S (1985) Some observations in man with a new extractive drug: Defibrotide. In: Davidson JF, Donati MB, Coccheri S (eds) Progress in fibrinolysis, vol. VII. Churchill Livingstone, Edinburgh, pp 327–328

    Google Scholar 

  22. Fitzgerald GA, Anders KD, Patrono C (1983) Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67: 1174–1177

    Google Scholar 

  23. Cizmëci G (1986) In vivo effects of Defibrotide on platelet cAMP and blood prostanoid levels. Haemostasis 16 [Suppl 1]: 31–35

    Google Scholar 

  24. Mullane KM, Read N, Salmon JA, Moncada S (1984) Role of leukocytes in acute myocardial infarction in anesthetized dogs: Relationship to salvage by antiinflammatory drugs. J Pharmacol Exp Ther 228: 510–515

    Google Scholar 

  25. Fumagalli G, Angelaccio E, Lombardo N, Clementi F (1987) Morphometric and ultrastructural study of experimental venous thrombosis. Effects of Defibrotide, an antithrombotic agent. Haemostasis 17: 361–371

    Google Scholar 

  26. Weksler BB, Goldestein IM (1980) Prostaglandins: Interaction with platelets and polymorphonuclear leukocytes in hemostasis and inflammation. Am J Med 68: 419–428

    Google Scholar 

  27. Blackwell GJ, Flower RJ, Russel-Smith N, Salmon JA, Thorogood PB, Vane JR (1978) Prostacyclin is produced in whole blood. Br J Pharmacol 64: 436

    Google Scholar 

  28. Jolly SR, Kane WJ, Hook BG, Abrams GD, Kunkel SL, Lucchesi BR (1986) Reduction of myocardial infarct size by neutrophil depletion: Effect of duration of occlusion. Am Heart J 112: 682–690

    Google Scholar 

  29. Levenson DJ, Simmons CE, Brenner BM (1982) Arachidonic acid, prostaglandins and the kidney. Am J Med 72: 354–360

    Google Scholar 

  30. Frasca' GM, Vangelista A, Raimondi C, Bonomini V (1986) Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (Defibrotide): A controlled study. Life Support Syst 4: 231–237

    Google Scholar 

  31. Bonomini V, Frasca' GM, Raimondi C, Liviano-Darcangelo G, Vangelista A (1985) Effect of a new antithrombotic agent (Defibrotide) in acute renal failure due to thrombotic microangiopathy. Nephron 40: 195–200

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chair of Medical Pathophysiology and Department of Angiology and Blood Coagulation, University Hospital S. Orsola, Bologna, Italy

    S. Coccheri, G. Biagi, C. Legnani, B. Bianchini & F. Grauso

Authors
  1. S. Coccheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Biagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Legnani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Bianchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Grauso
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coccheri, S., Biagi, G., Legnani, C. et al. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol 35, 151–156 (1988). https://doi.org/10.1007/BF00609244

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00609244

Key words

Search

Navigation